Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Agenus Inc
(NQ:
AGEN
)
5.800
+0.330 (+6.03%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Agenus Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Agenus (AGEN) Q2 2024 Earnings Call Transcript
August 08, 2024
AGEN earnings call for the period ending June 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
AGEN Stock Earnings: Agenus Misses EPS, Misses Revenue for Q2 2024
August 08, 2024
AGEN stock results show that Agenus missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Agenus Reports Second Quarter 2024 Operational and Financial Results
August 08, 2024
From
Agenus Inc.
Via
Business Wire
Agenus Announces Appointment of Tom Harrison to Board of Directors
August 08, 2024
From
Agenus Inc.
Via
Business Wire
Agenus Publishes Seminal Study on Botensilimab’s Activity in Treatment-Resistant Cancers
August 07, 2024
From
Agenus Inc.
Via
Business Wire
Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus
August 05, 2024
Agenus reports that Bristol Myers Squibb (NYSE: BMY) is ending their 2021 agreement, returning the TIGIT bispecific antibody AGEN1777. This decision is part of Bristol Myers' broader pipeline strategy...
Via
Benzinga
Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update
July 26, 2024
From
Agenus Inc.
Via
Business Wire
Agenus Faces Regulatory and Financial Challenges: Analyst Downgrades Stock Pending Trial Clarity
July 19, 2024
Agenus faces a setback as the FDA advises against accelerated approval for its immunotherapy combination, botensilimab and balstilimab, for relapsed/refractory microsatellite-stable colorectal cancer....
Via
Benzinga
Exposures
Product Safety
AGEN Investors Have Opportunity to Join Agenus Inc. Securities Fraud Investigation with the Schall Law Firm
July 18, 2024
From
Schall Law Firm
Via
Business Wire
Nasdaq Down Over 100 Points; Abbott Laboratories Earnings Beat Views
July 18, 2024
Via
Benzinga
Topics
Earnings
Exposures
Financial
Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
July 18, 2024
Via
Benzinga
Dow Dips 250 Points; US Weekly Jobless Claims Surge
July 18, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
WBD Stock Pops as Warner Bros. Considers Streaming Spinoff
July 18, 2024
Warner Bros. stock is rising on Thursday as reports about a potential spinoff of its streaming division embolden WBD investors.
Via
InvestorPlace
Agenus Loses More Than 50% Value On Thursday - Here's Why
July 18, 2024
Agenus shares drop amid FDA's feedback on its immunotherapy combo botensilimab and balstilimab for colorectal cancer. The FDA advised against accelerated approval, citing concerns about survival...
Via
Benzinga
Exposures
Product Safety
Why Is NKGen Biotech (NKGN) Stock Up 18% Today?
July 18, 2024
NKGen Biotech stock is up Thursday as NKGN holders react to plans for a presentation at the Alzheimer’s Association International Conference.
Via
InvestorPlace
Why Is Agenus (AGEN) Stock Down 55% Today?
July 18, 2024
Agenus stock is down on Thursday after the company provided AGEN investors with an update on a Phase 2 clinical trial meeting.
Via
InvestorPlace
US Stocks Edge Higher; D.R. Horton Posts Upbeat Earnings
July 18, 2024
Via
Benzinga
Agenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal Cancer
July 18, 2024
From
Agenus Inc.
Via
Business Wire
Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference
June 28, 2024
From
Agenus Inc.
Via
Business Wire
Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies
June 27, 2024
From
Agenus Inc.
Via
Business Wire
Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors
June 17, 2024
From
Agenus Inc.
Via
Business Wire
Nature Medicine Reports Agenus’ Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50
June 13, 2024
From
Agenus
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
June 05, 2024
Via
Benzinga
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
June 04, 2024
Via
Benzinga
Saia, Annexon, Core Scientific And Other Big Stocks Moving Higher On Tuesday
June 04, 2024
Via
Benzinga
Agenus Announces Virtual Annual Shareholders Meeting
June 04, 2024
From
Agenus Inc.
Via
Business Wire
Medical Moonshots: 3 Biotech Stocks Set to Skyrocket
May 30, 2024
Though risky, investors who buy biotech stocks watch their portfolios skyrocket when their drugs work as intended.
Via
InvestorPlace
7 Biotech Stocks to Put on Your Breakthrough Radar
May 27, 2024
Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance.
Via
InvestorPlace
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 24, 2024
From
Agenus Inc.
Via
Business Wire
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting
May 23, 2024
From
Agenus Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.